CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Heparin Sodium

肝素钠 杂质对照品Heparin Sodium Impurities

9 个杂质条目9 impurity entries

本页汇总 肝素钠 的 9 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 9 impurity reference standards of Heparin Sodium. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 肝素钠(Heparin Sodium)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDetermination of galactosamine impurities in heparin sodium using fluorescent labeling and conventional high-performance liquid chromatography
    Biologicals : journal of the International Association of Biological Standardization · 2013 · Itoh S et al.  ·  PMID 23827519  ·  DOI
  2. 杂质研究Impurity studiesAssay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches
    Journal of pharmaceutical and biomedical analysis · 2010 · Keire DA et al.  ·  PMID 20233649  ·  DOI
  3. 杂质研究Impurity studiesOligosaccharide Chromatographic Techniques for Quantitation of Structural Process-Related Impurities in Heparin Resulting From 2-O Desulfation
    Frontiers in medicine · 2018 · Anger P et al.  ·  PMID 30619858  ·  DOI
  4. 分析方法Analytical MethodsUSP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium
    Analytical and bioanalytical chemistry · 2014 · Mulloy B et al.  ·  PMID 24958344  ·  DOI
  5. 分析方法Analytical MethodsA simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins
    Journal of pharmaceutical and biomedical analysis · 2008 · Patel RP et al.  ·  PMID 18024047  ·  DOI

肝素钠 —— 原料药与杂质对照品Heparin Sodium — drug substance & impurities

共 9 个条目(含原料药本体)9 items incl. the drug substance
Heparin Sodium (Hepalean) structure
—
肝素钠 (海普林)Heparin Sodium (Hepalean)
Heparin Sodium (Hepalean)
CAS No.9041-08-1
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 1 (L-Iduronic Acid) structure
1
肝素钠杂质1 (L-艾杜糖醛酸)Heparin Sodium Impurity 1 (L-Iduronic Acid)
Heparin Sodium Impurity 1 (L-Iduronic Acid)
CAS No.2073-35-0
Chemical FormulaC6H10O7
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 2 Monomer (Heparin Disaccharide I-H) structure
2
肝素钠杂质2 单体 (肝素二糖 I-H)Heparin Sodium Impurity 2 Monomer (Heparin Disaccharide I-H)
Heparin Sodium Impurity 2 Monomer (Heparin Disaccharide I-H)
CAS No.123228-41-1
Chemical FormulaC12H19NO16S2
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 2 (Heparin Disaccharide I-H Trisodium Salt) structure
2
肝素钠杂质2 (肝素二糖 I-H 三钠盐)Heparin Sodium Impurity 2 (Heparin Disaccharide I-H Trisodium Salt)
Heparin Sodium Impurity 2 (Heparin Disaccharide I-H Trisodium Salt)
CAS No.136098-04-9
Chemical FormulaC12H16NO16S23-·3Na+
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 3 Monomer (Heparin Disaccharide II-H) structure
3
肝素钠杂质3 单体 (肝素二糖 II-H)Heparin Sodium Impurity 3 Monomer (Heparin Disaccharide II-H)
Heparin Sodium Impurity 3 Monomer (Heparin Disaccharide II-H)
CAS No.123228-40-0
Chemical FormulaC12H19NO13S
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 3 (Heparin Disaccharide II-H Disodium Salt) structure
3
肝素钠杂质3 (肝素二糖 II-H 二钠盐)Heparin Sodium Impurity 3 (Heparin Disaccharide II-H Disodium Salt)
Heparin Sodium Impurity 3 (Heparin Disaccharide II-H Disodium Salt)
CAS No.136098-02-7
Chemical FormulaC12H17NO13S2-·2Na+
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 4 (Heparin Disaccharide III-H Disodium Salt) structure
4
肝素钠杂质4 (肝素二糖 III-H 二钠盐)Heparin Sodium Impurity 4 (Heparin Disaccharide III-H Disodium Salt)
Heparin Sodium Impurity 4 (Heparin Disaccharide III-H Disodium Salt)
CAS No.136098-01-6
Chemical FormulaC12H17NO13S2-·2Na+
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 4 Monomer (Heparin Disaccharide III-H) structure
4
肝素钠杂质4 单体 (肝素二糖 III-H)Heparin Sodium Impurity 4 Monomer (Heparin Disaccharide III-H)
Heparin Sodium Impurity 4 Monomer (Heparin Disaccharide III-H)
CAS No.138692-82-7
Chemical FormulaC12H19NO13S
Purity>95%询价On request
10mg25mg50mg100mg
Heparin Sodium Impurity 5 (Heparin Disaccharide IV-H) structure
5
肝素钠杂质5 (肝素二糖 IV-H)Heparin Sodium Impurity 5 (Heparin Disaccharide IV-H)
Heparin Sodium Impurity 5 (Heparin Disaccharide IV-H)
CAS No.123228-39-7
Chemical FormulaC12H19NO10
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

肝素钠 —— 研究文献与合成路线Heparin Sodium — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 肝素钠 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Heparin Sodium. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities
    Trehy ML, Reepmeyer JC, Kolinski RE, et al. · Journal of pharmaceutical and biomedical analysis · 2009 · 被引 60cited 60
  2. Determination of galactosamine impurities in heparin sodium using fluorescent labeling and conventional high-performance liquid chromatography
    Itoh S, Hiruta Y, Hashii N, et al. · Biologicals : journal of the International Association of Biological Standardization · 2013 · 被引 1cited 1
  3. Purification of heparin sodium salt by enzymatic degradation
    Zhou Xianwan, He Wei · Zhongguo sheng wu hua xue yu fen zi sheng wu xue bao = Chinese journal of biochemistry and molecular biology · 1999

合成与制备工艺专利Synthesis & process patents

  1. Resin enzymolysis process for heparin sodium
    JINLIN LU, JIE WANG, SHAOBO ZHANG, XIEPING LI, et al. · 公开号 CN101368196CN101368196 · 2009
  2. Process for extracting aprotinin and heparin sodium from cattle lung
    SU HAN SU · 公开号 CN1803829CN1803829 · 2006
  3. Low molecular weight heparin sodium and affinity chromatography preparation method thereof
    SU HAN SU · 公开号 CN1803853CN1803853 · 2006
  4. Joint production process joint production producing alkaline phosphatase and heparin sodium with pig small intestine as raw material
    ZHANGCUN WANG, XUEJUN WU, BIN WANG · 公开号 CN101182495CN101182495 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

肝素钠 杂质谱研究要点Heparin Sodium — impurity profiling notes

下面这些是拿到 肝素钠 的 9 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 9 impurity entries for Heparin Sodium, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances